10-K: Silexion Faces Going Concern Doubt Amidst R&D Push

Silexion Therapeutics Corp reports significant losses and substantial doubt about its ability to continue as a going concern, despite advancing its lead oncology candidate, SIL204, towards Phase 2/3 clinical trials.

Summary

• Silexion Therapeutics Corp is a clinical-stage oncology-focused biotechnology company developing RNA-interference (RNAi) treatments for KRAS-driven cancers.
• The lead product candidate, SIL204, is a second-generation siRNA therapy targeting mutated KRAS proteins, particularly for locally advanced pancreatic cancer (LAPC) patients with KRAS G12D/V mutations.
• A previous Phase 2 trial with the first-generation siRNA (siG12D-LODER) showed a trend for a 9.3-month overall survival benefit in KRAS G12D/V LAPC patients when combined with standard-of-care chemotherapy.
• Preclinical studies for SIL204 demonstrated stability, broad silencing activity across various KRAS mutations (G12D, G12V, G12C, G12R, Q61H, G13D), and synergistic effects with standard chemotherapeutic agents.
• Toxicology studies for SIL204 in 2025 confirmed no systemic organ toxicity and established safety margins of up to 11-fold over the clinical starting dose.
• The company incurred net losses of $11.9 million for the year ended December 31, 2025, and $16.5 million for 2024, with an accumulated deficit of $55.2 million as of December 31, 2025.
• Cash and cash equivalents were $6.0 million as of December 31, 2025, and the company expects current funds to be sufficient for only several months from the filing date.
• Silexion successfully regained compliance with Nasdaq listing requirements for shareholders' equity and minimum bid price in September 2025, but remains under a mandatory panel monitoring period until September 23, 2026.
• The company raised approximately $11.0 million gross from public offerings in January and September 2025, and $5.0 million gross from warrant exercise inducement transactions in January and August 2025.
• An At-The-Market (ATM) Offering Agreement was established in September 2025 to raise up to $13.17 million, though no sales occurred under it in 2025.
• A proposed increase in authorized share capital to 59,000,000 ordinary shares is pending shareholder approval at a reconvened extraordinary general meeting on March 23, 2026, to support future financing needs.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with low sentiment due to the explicit 'going concern' doubt and recurring losses, which overshadow the positive preclinical and early clinical data for SIL204. The significant and ongoing need for capital raises substantial financial risk for investors.

Positives

• SIL204 preclinical studies demonstrated enhanced stability, improved tumor cell uptake, and broader silencing activity across multiple KRAS mutations compared to the first-generation product.
• Toxicology studies for SIL204 completed in 2025 confirmed no systemic organ toxicity and established safety margins up to 11-fold over the clinical starting dose.
• The German regulatory authority (BfArM) agreed in principle to the planned design of the Phase 2/3 trial for SIL204.
• A previous Phase 2 clinical trial with the first-generation siRNA (siG12D-LODER) showed a positive trend for a 9.3-month increase in median overall survival in KRAS G12D/V LAPC patients when combined with standard chemotherapy.
• The company successfully regained compliance with Nasdaq's minimum bid price and shareholders' equity requirements in September 2025, avoiding delisting.
• Significant capital was raised through public offerings ($11.0 million gross) and warrant exercise inducement transactions ($5.0 million gross) in 2025.
• The company has a patent application for SIL204 as a composition and for use in treatment of pancreatic and other cancers, with expected protection until 2043 plus estimated extension to 2048.

Negatives

• The company has incurred significant net losses since inception, totaling $11.9 million in 2025 and $16.5 million in 2024, with an accumulated deficit of $55.2 million.
• There is substantial doubt about the company's ability to continue as a going concern, with current cash and cash equivalents ($6.0 million) expected to fund operations for only several months.
• The company has never generated any revenue from product sales and does not anticipate doing so for the foreseeable future.
• The approach of developing novel RNAi therapeutics for oncology is unproven and may never lead to marketable products.
• The company is heavily dependent on the success of SIL204, which is still in early clinical development, with no assurance of regulatory approval.
• The market for SIL204, targeting specific KRAS mutations in LAPC, is relatively small, requiring significant market share to achieve profitability.
• The company has no commercial manufacturing, marketing, or sales organization, which will require substantial investment and time to establish.
• The A&R Sponsor Promissory Note holder (Moringa Sponsor) disputes a $1.8 million conversion into ordinary shares and has demanded full repayment of the note.

Risks

• We are a development-stage company with a limited operating history and have incurred significant losses since inception, with no revenue from product sales.
• We will need to raise substantial additional funding, which may not be available on acceptable terms or at all, leading to significant dilution for shareholders.
• Our independent registered public accounting firm's report contains an explanatory paragraph expressing substantial doubt about our ability to continue as a going concern.
• The RNAi therapeutic approach for oncology is unproven and may never lead to marketable products, with potential challenges like off-target effects and interferon response.
• We are heavily dependent on the success of SIL204, which is in early clinical development, and may not receive regulatory approval.
• The regulatory approval processes are lengthy, expensive, and unpredictable, and we may be unable to obtain approval for our product candidates.
• Clinical drug development is a lengthy and expensive process with uncertain outcomes, and preclinical/early-stage results may not predict future study results.
• Difficulty enrolling patients in clinical studies could delay or prevent the completion of trials, especially for rare diseases like LAPC with specific KRAS mutations.
• SIL204 or its administration may cause undesirable side effects, delaying or preventing regulatory approval, limiting commercial profile, or resulting in negative consequences post-approval.
• Even if approved, our products will remain subject to regulatory scrutiny, and failure to comply could lead to sanctions or withdrawal of approval.
• We are subject to manufacturing risks, including contamination, equipment failure, or supply disruptions, which could increase costs and limit supply.
• Reliance on third parties for preclinical/clinical studies and manufacturing entails risks of non-compliance, delays, and potential disclosure of trade secrets.
• If market opportunities for our product candidates are smaller than estimated, revenue may be adversely affected.
• We lack experience in commercial-level production and have not secured binding agreements with third-party manufacturers for commercialization.
• Intense competition and rapid technological change in the biotechnology and pharmaceutical industries may lead competitors to develop more effective or less costly therapies.
• We currently have no marketing and sales organization, and failure to establish one or secure third-party agreements could prevent revenue generation.
• The market may not be receptive to our product candidates based on a novel therapeutic modality (RNAi), affecting market acceptance and revenue.
• Uncertainty regarding insurance coverage and reimbursement for newly-approved products could limit marketability and revenue generation.
• Healthcare legislative reforms and cost-containment measures may negatively affect our business and profitability.
• Our product candidates may be approved only as neoadjuvant or adjuvant therapy, limiting commercialization.
• Inability to obtain and maintain effective patent rights for our product candidates could impair our ability to compete effectively.
• Third-party claims of intellectual property infringement may prevent or delay development and commercialization efforts, leading to costly litigation or licensing requirements.
• We may not have sufficient patent terms to effectively protect our products and business, leading to earlier generic competition.
• Patent law changes or interpretations could increase uncertainties and costs in patent prosecution and enforcement.
• The U.S. federal government retains march-in rights for inventions produced with financial assistance, potentially allowing third-party licensing based on pricing or access.
• Loss of key personnel would negatively affect our business, and we may be unable to attract and retain additional skilled employees.
• Computer system failures, cyberattacks, or cybersecurity deficiencies could materially affect our operations and financial results.
• Product liability lawsuits could result in substantial liabilities and limit commercialization of approved products.
• Inability to successfully identify and execute strategic alliances or manage acquisitions/dispositions could adversely affect operations.
• Conditions in the Middle East and Israel, where our operations are centered, may harm our operations, including ability to raise financing.
• It may be difficult to enforce U.S. judgments against us, our officers, or directors in Israel, or to assert U.S. securities law claims.
• We may be unable to enforce non-compete covenants with former employees, allowing competitors to benefit from their expertise.
• Failure to maintain compliance with Nasdaq listing requirements could lead to delisting, reducing liquidity and increasing share price volatility.
• The price of our ordinary shares and warrants may be volatile due to various factors, including market fluctuations and company-specific announcements.
• Substantial issuance of ordinary shares through ATM or promissory note conversions could cause significant dilution and depress share price.
• We have no current plans to pay cash dividends, so investors may only receive a return by selling shares at a higher price.
• Additional reverse share splits could lead to extreme price volatility unrelated to performance.
• Our status as an emerging growth company and smaller reporting company allows for certain disclosure exemptions, which may make our securities less attractive to some investors.
• Our PFIC status could result in adverse U.S. federal income tax consequences to U.S. Holders.
• If a U.S. person owns at least 10% of our shares, they may be subject to adverse U.S. federal income tax consequences as a United States shareholder of a Controlled Foreign Corporation (CFC).

Future Outlook

The company expects to initiate the first part of its Phase 2/3 clinical studies for SIL204 in the second quarter of 2026, with applications for trials in additional EU countries expected in early 2027, and an IND submission to the FDA in Q1 2027. The initial stage will involve a safety run-in in approximately 18 patients, followed by an expanded randomized study of approximately 166 patients. The company also plans to apply for Orphan Drug Designation in the U.S. and EU in H1 2027 and will focus on expanding its pipeline with additional preclinical studies for other oncological indications of SIL204 throughout 2026.

Management Comments

• "We believe SIL204 has the potential to further improve clinical outcomes, by improving uptake into tumor cells, enhancing stability, and broadening the scope of its silencing activity."
• "We believe the optimization of our siRNA and moving to the second generation product allows for more of a personalized medicine approach to the dosing, allowing the siRNA dose to be adjusted to the tumor size."
• "We believe that the conversion [of the A&R Sponsor Promissory Note] was carried out in strict compliance with the substantive and procedural requirements of the note, and reject any claim to the contrary."

Industry Context

StockSavvy.ai notes that Silexion Therapeutics operates in the highly competitive and rapidly evolving oncology biotechnology sector, specifically targeting KRAS-driven cancers with RNAi therapeutics. While KRAS has historically been a challenging target, recent approvals of small molecule KRAS inhibitors (e.g., Amgen, Bristol-Myers Squibb for KRAS G12C in NSCLC) validate KRAS as a druggable target. Silexion's differentiated approach of silencing the oncogene itself, rather than inhibiting the protein, positions it uniquely against competitors like Revolution Medicines, AstraZeneca, Pfizer, and Lilly, who are pursuing various KRAS inhibition strategies. The validation of siRNA technology in non-oncological indications also provides a foundational context for Silexion's platform, though its application in oncology remains less proven. The integrated intratumoral and systemic delivery approach for pancreatic cancer aims to overcome challenges posed by the tumor's dense stroma, a significant unmet need in this particularly aggressive cancer type.

Comparison to Industry Standards

• The median overall survival (OS) of 13.4 months in the standard-of-care chemotherapy group in Silexion's Phase 2 trial (siG12D-LODER) is consistent with literature findings for non-resectable locally advanced pancreatic cancer, as referenced by Gemenetzis, G. et al, 2019.
• The observed 9.3-month numerical advantage in OS for the Loder + SoC group (22.7 months vs. 13.4 months) in a small subset of KRAS G12D/V patients, while not statistically significant, suggests a positive trend compared to standard treatments.
• Silexion's siRNA technology prevents KRAS protein production, a key distinction from existing small molecule KRAS inhibitors (e.g., Amgen, Bristol-Myers Squibb) which inhibit the protein after it is functioning, potentially offering an earlier intervention point in the oncogenic process.
• The good safety profiles of marketed siRNA products for non-oncology indications support the general safety premise of Silexion's siRNA technology, although oncology applications may present unique challenges.

Corporate Governance

Legal Proceedings

• The company is not currently subject to any material legal proceedings.
• The Moringa Sponsor has notified the company that it disputes the conversion of $1.8 million of the A&R Sponsor Promissory Note into ordinary shares and has demanded full repayment of the note. The company believes the conversion was in strict compliance with the note's terms and rejects the claim.

Related Party Transactions

• Ilan Hadar (CEO and Chairman) and Mirit Horenshtein Hadar (CFO and Secretary) are married. Their employment agreements with Silexion Israel provide for annual base salaries of $382,398 and $250,297, respectively, plus customary benefits.
• Dr. Mitchell Shirvan (Chief Scientific and Development Officer) has an employment agreement with Silexion Israel providing a gross monthly salary of NIS 80,000 (annual base salary of $278,108) plus customary benefits.
• Indemnification agreements were entered into with each director and executive officer on August 15, 2024, providing for indemnification and expense advancements.
• Greenstar, LP, an affiliate of the Moringa sponsor, participated in a PIPE financing on August 15, 2024, purchasing 1,482 Moringa ordinary shares (converted to Silexion ordinary shares) for $2.0 million. Greenstar, LP is entitled to customary registration rights for these shares.
• The Amended and Restated Sponsor Promissory Note, in an original principal amount of $3,433,000, was issued to the Moringa sponsor on August 15, 2024. As of September 30, 2025, $1,633,000 remained outstanding after a $1.8 million conversion into 450,000 ordinary shares on September 15, 2025.
• The Moringa Sponsor (controlled by director Ilan Levin) disputes the $1.8 million conversion of the promissory note and has demanded full repayment.
• Ilan Levin, a director, receives a consulting fee of $10,000 per month ($120,000 annually).
• Dr. Shlomo Noy, a director, receives a consulting fee of $10,000 per month, effective November 2025.
• Guangzhou Sino-Israel Biotech Fund (GIBF), with which directors Avner Lushi and Shlomo Noy are affiliated, holds ordinary shares and options in Silexion.
• Certain security holders, including those who beneficially owned 5% or more of outstanding ordinary shares, participated in warrant exercise inducement transactions in January and August 2025, resulting in the exercise of existing warrants and issuance of new warrants.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from ongoing and future equity financings (public offerings, warrant exercises, ATM, promissory note conversions) due to the company's substantial funding needs. The 'going concern' doubt and potential delisting risk (if Nasdaq compliance is not maintained) pose a material threat to investment value. The dispute over the A&R Sponsor Promissory Note adds uncertainty.
• **Employees:** The company plans to hire additional personnel to support R&D and growth, which could be positive for employment. However, the 'going concern' doubt introduces job security concerns.
• **Customers (Future):** Successful development and commercialization of SIL204 could provide a novel treatment option for KRAS-driven cancers, particularly LAPC, addressing a significant unmet medical need.
• **Suppliers/Vendors:** The company relies heavily on third-party CROs and contract manufacturers. Continued operations and funding are crucial for these relationships. Delays in payments or termination of programs due to funding issues could negatively impact these partners.
• **Creditors:** The 'going concern' doubt and reliance on equity financing for liquidity pose risks to creditors, particularly those holding the remaining A&R Sponsor Promissory Note, especially given the dispute over its conversion.

Next Steps

• Initiate the first part of Phase 2/3 clinical studies for SIL204 in the second quarter of 2026.
• Submit an application to BfArM (Germany) to conduct clinical studies in Germany in Q1 2026.
• Submit applications for trials in additional European Union countries early in 2027.
• Submit an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) in Q1 2027.
• Complete the safety run-in stage of the Phase 2/3 clinical trial (approximately 18 patients) within the first year of initiation.
• Expand into a second stage of the Phase 2/3 clinical trial, including a randomized study of approximately 166 patients, subject to successful completion of the safety run-in.
• Conduct an interim analysis for sample size adjustment and futility between the Phase 2 and Phase 3 segments of the trial.
• Focus on the clinical development of SIL204 in the Phase 2/3 trial throughout 2026.
• Expand the pipeline with additional preclinical studies for additional oncological indications of SIL204 throughout 2026.
• Initiate the toxicology program sufficient for a marketing application in 2026.
• Apply for Orphan Drug Designation in both the U.S. and EU in H1 2027.
• Obtain shareholder approval for an additional increase in authorized share capital at the reconvened extraordinary general meeting on March 23, 2026.

Key Dates

Recommendation

The filing explicitly states 'substantial doubt about our ability to continue as a going concern' and that current cash will only fund operations for 'several months.' This is a critical red flag for any investor. While the company has positive preclinical data and a promising lead candidate, the severe liquidity crisis, recurring significant losses, and the need for continuous, dilutive capital raises (including a pending shareholder vote for increased authorized capital) indicate extreme financial instability. The dispute over the A&R Sponsor Promissory Note further exacerbates financial uncertainty. The high-risk profile, coupled with the early stage of clinical development and intense competition in oncology, makes this a 'strong sell' for any seasoned investor or institution, as the risk of capital loss is exceptionally high.

Keywords

Silexion Therapeutics, SLXN, Biotechnology, Oncology, KRAS-driven cancers, RNAi therapeutics, siRNA, SIL204, Pancreatic cancer, LAPC, Clinical trials, Phase 2/3, Drug development, Nasdaq listing, Going concern, Capital raise, Warrants, Intellectual property, Biopharmaceutical, Israel